Pharming Group NV Market Cap ($902.47 Million)
Market Cap & Net Worth: Pharming Group NV (PHARM)
Pharming Group NV market cap. Pharming Group NV (AS:PHARM) has a market capitalization of $902.47 Million (€771.93 Million) as of November 7, 2026. Listed on the AS stock exchange, this Netherlands-based company holds position #9086 globally and #54 in its home market, demonstrating a 1.79% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Pharming Group NV's stock price €1.11 by its total outstanding shares 696688239 (696.69 Million). Also see Pharming Group NV (PHARM) cash conversion ratio for how efficiently the company converts equity into cash flow.
Pharming Group NV Market Cap History (2015–2026)
Pharming Group NV market cap history from 2015 to 2026. Data shows growth from $227.98 Million to $902.47 Million (12.29% CAGR). Check PHARM share price today for real-time trading data and today's change.
Index Memberships
Pharming Group NV is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
AMS Small Cap
ASCX
|
$12.29 Billion | 7.34% | #4 of 21 |
Weight: Pharming Group NV's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Pharming Group NV Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Pharming Group NV's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore net asset growth rate of Pharming Group NV to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
2.63x
Pharming Group NV's market cap is 2.63 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $227.98 Million | $11.84 Million | -$10.89 Million | 19.26x | N/A |
| 2016 | $176.75 Million | $16.69 Million | -$18.44 Million | 10.59x | N/A |
| 2017 | $922.02 Million | $107.52 Million | -$95.92 Million | 8.58x | N/A |
| 2018 | $616.99 Million | $154.58 Million | $28.59 Million | 3.99x | 21.58x |
| 2019 | $1.28 Billion | $189.33 Million | $40.54 Million | 6.74x | 31.49x |
| 2020 | $1.04 Billion | $228.39 Million | $37.75 Million | 4.54x | 27.45x |
| 2021 | $631.24 Million | $189.85 Million | $16.00 Million | 3.32x | 39.46x |
| 2022 | $882.92 Million | $205.62 Million | $13.67 Million | 4.29x | 64.57x |
| 2023 | $839.75 Million | $226.91 Million | -$9.76 Million | 3.70x | N/A |
| 2024 | $753.41 Million | $286.89 Million | -$10.64 Million | 2.63x | N/A |
Competitor Companies of PHARM by Market Capitalization
Companies near Pharming Group NV in the global market cap rankings as of November 7, 2026. Also see Pharming Group NV assets under control for a full breakdown of the balance sheet.
Key companies related to Pharming Group NV by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #176 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #364 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #405 globally with a market cap of $69.48 Billion USD ( AU$98.19 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #499 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #176 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $542.50 |
| #364 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $902.90 |
| #405 | CSL Ltd | AU:CSL | $69.48 Billion | AU$202.40 |
| #499 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $241.46 |
Market Capitalization of Pharming Group NV (2015–2026)
Market capitalization of Pharming Group NV from 2015 to today. Between 2015 and today, Pharming Group NV's market cap moved from $227.98 Million to $ 902.47 Million, with a yearly change of 12.29%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €902.47 Million | -22.30% |
| 2025 | €1.16 Billion | +54.16% |
| 2024 | €753.41 Million | -10.28% |
| 2023 | €839.75 Million | -4.89% |
| 2022 | €882.92 Million | +39.87% |
| 2021 | €631.24 Million | -39.07% |
| 2020 | €1.04 Billion | -18.85% |
| 2019 | €1.28 Billion | +106.93% |
| 2018 | €616.99 Million | -33.08% |
| 2017 | €922.02 Million | +421.66% |
| 2016 | €176.75 Million | -22.47% |
| 2015 | €227.98 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 6th, 2026 the market cap of Pharming Group NV was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $902.47 Million USD |
| MoneyControl | $902.47 Million USD |
| MarketWatch | $902.47 Million USD |
| marketcap.company | $902.47 Million USD |
| Reuters | $902.47 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Pharming Group NV
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE… Read more